Epicardial obesity and atrial fibrillation: emphasis on atrial fat depot

Obesity and metabolism, Journal Year: 2020, Volume and Issue: 17(3), P. 316 - 325

Published: Dec. 6, 2020

The studies, performed with MRI and CT, showed that the increase of fat, immediately adjacent to myocardium (epicardial fat) is correlated more strongly risk atrial fibrillation than general or abdominal obesity. According some epicardial fat around left atrium a strong predictor development at fibrillation. Also, amount associated effectiveness cardioversion developing thromboembolic stroke in patients number such works small, since tomographic examinations are not needed if intra-atrial thrombosis suspected, transthoracic echocardiograthy does allow visualization fat. However, transesophageal echocardiography widely used allows measure structures serve as depots namely interatrial septum lateral ridge. Accumulation leads thickening these structures. This can be study relationship between obesity complications fibrillations.

Language: Английский

---

Ожирение и ассоциированные с ним заболевания – проблемные вопросы патогенеза и современные стратегии диагностики и лечения

Актуальные проблемы медицины, Journal Year: 2023, Volume and Issue: 46(2), P. 123 - 143

Published: June 30, 2023

Изучение механизмов патологического влияния ожирения на развитие, течение и исходы ряда социально значимых заболеваний, поиск эффективных мер их лечения профилактики находятся в ряду приоритетных задач современной медицинской науки здравоохранения. Накопленная по этой проблеме информация последних десятилетий демонстрирует необходимость новой стратегии для клинической практики, внедрения междисциплинарных подходов к диагностике ассоциированной с ним патологии включением детального метаболического фенотипирования лиц, страдающих ожирением, персонализированного подхода лечению. Перед специалистами практического здравоохранения остро стоит задача своевременного определения у пациентов ожирением степени сердечно-сосудистого риска, ранней диагностики нарушений углеводного обмена, выбора методов безопасной терапии разработки мероприятий его хронических осложнений. В данном обзоре проанализированы литературные материалы о патогенезе развития ассоциированных заболеваний сформулированы современные стратегические подходы диагностике, лечению профилактике данной патологии.

Language: Русский

---

Heterogeneity of obesity phenotypes in relation to cardiovascular risk

CARDIOVASCULAR THERAPY AND PREVENTION, Journal Year: 2019, Volume and Issue: 18(1), P. 161 - 167

Published: March 1, 2019

Obesity is associated with numerous metabolic disorders, the development and progression of a wide range conditions diseases, primarily cardiovascular disease type 2 diabetes. One widely discussed phenomena association obesity their complications mortality phenomenon “heterogeneity phenotypes in relation to risk”. Currently, two main have been identified — metabolically healthy unhealthy obesity. At same time, not only expediency separation, but also existence this phenotype today. The article provides an overview existing approaches verification data relating epidemiology risk diseases death, discusses factors that determine features phenotype.

Language: Английский

---

“Obesity paradoxes”: main causes of an “inverse” cardiovascular epidemiology

CARDIOVASCULAR THERAPY AND PREVENTION, Journal Year: 2018, Volume and Issue: 17(5), P. 92 - 98

Published: Nov. 15, 2018

Taken the continuous increase of obesity prevalence, most countries in world deal with an epidemy, one main healthcare concerns. In structure nosology associated overweight and obesity, cardiovascular is leading. Also, recent trials meta analyses there negative correlation found for body mass index clinical outcomes characterizing better survival lower events rate those higher BMI, as less chronic diseases. Such facts facilitated a number discussions on predictive value consideration whether to correct patients secondary prevention. Current article focused causes “inverse” epidemiology obesity.

Language: Английский

---

Endothelial dysfunction in patients with obesity

Regional blood circulation and microcirculation, Journal Year: 2022, Volume and Issue: 21(3), P. 4 - 11

Published: Oct. 11, 2022

Endothelial dysfunction has been considered in the pathogenesis of obesity widespread population. The purpose this review was to provide updated information about pathogenetic features and markers endothelial obese patients. We mentioned systemic disorders obesity, such as oxidative stress, an increase pro-inflammatory cytokines – tumor necrosis factor alpha, interleukin-6, arginase activity. also discussed role insulin resistance development dysfunction, well product adipose tissue metabolism monocyte chemoattractant protein-1. participation perivascular tissue, hyperoxia regulation inflammation considered. illustrated influence atherogenic concentrations oxidized low-density lipoproteins, asymmetric dimethyl-L-arginine level on function. Changes laboratory parameters were analyzed: endothelin-1, levels microalbuminuria, homocysteine uric acid. described cytological (circulating vascular cells, microparticles) instrumental (endothelium-dependent vasodilation, peripheral arterial tonometry, intima-media complex thickness common carotid artery, ultrasound kidneys examination with duplex scanning renal arteries) methods for assessing Factors that risk cardiovascular complications hypertension stiffness, high lipoprotein triglycerides, reduced physical determination function patients can be important predicting pathology system. Information assessment may expand possibilities early diagnosis prevention complications.

Language: Английский

---

Clinical features of endothelial dysfunctions in patients with obesity and role of smoking

Regional blood circulation and microcirculation, Journal Year: 2018, Volume and Issue: 17(2), P. 18 - 25

Published: June 30, 2018

Introduction and purpose. The article presents data on the obesity endothelial dysfunction, influence of smoking developing dysfunction. Material methods. Examined 108 patients (90 women 18 men) with aged 45 to 65 years old (middle age 54.62±0.43) different degrees obesity. Vasomotor function was evaluated by method Celermajer et al. Analyzed early markers dysfunction in metabolic syndrome. Statistical processing using a nonparametric Wilcoxon-Konovalov Mann-Whitney. Conclusions. Based study preliminary conclusions can be made importance identifying these how influences vascular pathology

Language: Английский

---

The experience of sibutramine administration in patients with obesity and controlled arterial hypertension

Obesity and metabolism, Journal Year: 2019, Volume and Issue: 16(2), P. 42 - 48

Published: Sept. 16, 2019

BACKGROUND: Obesity is a metabolic disorder that becomes epidemic. Visceral adiposity increases the risk of arterial hypertension, diabetes mellitus and other comorbidities. According to this, main aim obesity treatment not only weight loss but also decrease AIMS: assess efficiency safety sibutramine in patients with evaluate drug influence on epicardial fat thickness. MATERIALS AND METHODS: 57 aged 35-60 hypertension were included study. All at beginning after 7 months follow-up underwent complex examination including anthropometric measurement, ECG, office ambulatory blood pressure echocardiography. Patients controlled included. During first month given general recommendations. Then was added. Control visits held 1 6 follow-up. RESULTS: Women predominated among study participants. approved by measurements all patients. Most had impaired left ventricle geometry: concentric remodeling or hypertrophy. mild: 2 kg (less than 2%) average. Sibutramine for increased: 3.7 (more After administration consisted 8.6 (6.2%) echocardiography results indexed mass LV myocardium decreased more significantly women. Also this group significant thickness revealed. Adverse events revealed 26.3% The most frequent constipation (12.3%) dry mouth (10.6%). severity symptoms persisted then decreased, additional therapy required. CONCLUSIONS: promotes effective loss, influences adipose tissue distribution, decreases progress associated an safe can be used visceral hypertension.

Language: Английский

---

Promising areas of pharmacotherapy for obesity

Russian Journal of Cardiology, Journal Year: 2021, Volume and Issue: 26(3), P. 4279 - 4279

Published: April 16, 2021

The increasing prevalence of obesity, accompanied by an increase in the frequency metabolic disorders, hypertension, associated conditions and diseases, dictates need to optimize preventive therapeutic strategies health care system, including pharmacological approaches correcting obesity related risk. evolution this area led both disappearance drugs that risks cardiovascular events, cancer, mental disorders or having other pronounced adverse effects, emergence unique not only lead a decrease body mass index, but also allow multifactorial effect on various components adiposopathy visceral among which glucagon-like peptide-1 receptor agonist liraglutide is currently registered with indication for obesity. In regard, study continues regard representatives class, as well from sodium-glucose cotransporter-2 inhibitors group. Many promising agents are being studied, review presented article.

Language: Английский

---

Identifying Early Vascular Ageing in Patients With Metabolic Syndrome: Unresolved Issues and a Proposed Novel VAmets Score

Heart Lung and Circulation, Journal Year: 2021, Volume and Issue: 30(11), P. 1752 - 1761

Published: Aug. 20, 2021

Language: Английский

---

Role of retinol binding protein 4, visfatin, omentin-1 and vaspin in gout patients with various obesity phenotypes

Russian Journal of Cardiology, Journal Year: 2024, Volume and Issue: 29(5), P. 5871 - 5871

Published: April 2, 2024

Aim. To study the serum level of retinol-binding protein 4 (RBP4), visfatin, omentin-1 and vaspin in gout patients with different obesity phenotypes, as well to assess dynamics studied parameters against background weight loss using an analog glucagon-like peptide-1 (GLP-1) liraglutide. Material methods. A total 117 men during attack-free interval were examined. The divided into 2 following groups: 1 st group consisted 43 a metabolically healthy (MHO) body mass index (BMI) ≥30 kg/m ; second 74 people unhealthy (MUO) (carbohydrate metabolism disorders, hypertension (HTN) BMI ). control was represented by 38 respondents class MHO. blood concentrations RBP4, omentin-1, vaspin, uric acid, high-sensitivity C-reactive (hsCRP), HOMA-IR, anthropometric at enrollment 12 weeks later on liraglutide therapy. Results. In obesity, increase RBP4 visfatin levels revealed simultaneous decrease compared no metabolic disorders. interrelationships syndrome components established: BMI, increased triglycerides (TGs), cholesterol, hsCRP, HOMA-IR hyperinsulinemia, reduced showed only positive relationship HDL-C concentration (p<0,05). Visfatin positively correlates diastolic pressure (r=0,29, p<0,01), number involved joints (r=0,577, attacks (r=0,63, p<0,001). Conclusion. correlate insulin sensitivity, whereas demonstrates association hyperuricemia severity gouty arthritis. Liraglutide therapy contributes 11,0±5,7%, improves profile gout, increasing content lowering acid concentration.

Language: Английский

---